Dow Jones' Pfizer is making a big push into gene therapy manufacturing as it tackles Duchenne muscular dystrophy and hemophilia B, rivaling Sarepta Therapeutics and Spark Therapeutics.
Dow Jones' Pfizer is making a big push into gene therapy manufacturing as it tackles Duchenne muscular dystrophy and hemophilia B, rivaling Sarepta Therapeutics and Spark Therapeutics.